Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

WARSAW, Ind., June 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 45th Annual Healthcare Conference on Tuesday, June 11, 2024, at 8:40 a.m.

Zimmer Biomet to Present at the Goldman Sachs 45th Annual Healthcare Conference

Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.

Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?

WARSAW, Ind. , May 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it will host an Investor Day on Wednesday, May 29, 2024, at 1:00 p.m.

Zimmer Biomet Announces 2024 Investor Day

Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now

WARSAW, Ind. , May 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2024.

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024

Sustainability report highlights progress in product quality and safety, environmental and greenhouse gas emissions goals, and team member engagement and development WARSAW, Ind. , May 6, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today published its 2023 Sustainability Report which provides an overview of the company's environmental, social and governance (ESG) program, progress, and accomplishments.

Zimmer Biomet Publishes 2023 Sustainability Report

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Keri Mattox - Chief Communications and Administration Officer Ivan Tornos - President and CEO Suky Upadhyay - Executive Vice President, Finance, Operations and Supply Chain, and CFO Conference Call Participants Travis Steed - Bank of America Steve Lichtman - Oppenheimer & Company Vik Chopra - Wells Fargo Rick Wise - Stifel Imron Zafar - Deutsche Bank Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Robbie Marcus - JPMorgan Chris Pasquale - Nephron Shagun Singh - RBC Operator Good morning, ladies and gentlemen. And welcome to the Zimmer Biomet First Quarter 2024 Earnings Conference Call.

Zimmer Biomet Holdings, Inc. (ZBH) Q1 2024 Earnings Call Transcript

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.

Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand

Hershey

Marathon Petroleum

Although the demand for inflation-resistant stocks has fallen in the past six to 12 months as consumer prices have moderated, JPMorgan Chase (NYSE: JPM ) CEO Jamie Dimon isn't convinced inflation has gone the way of the dodo bird.  “Many key economic indicators today continue to be good and possibly improving, including inflation.

Worried About Inflation? 3 Stocks Built to Thrive in a High-Price Environment

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zimmer (ZBH) Reports Q1 Earnings: What Key Metrics Have to Say

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $1.89 per share a year ago.

Zimmer Biomet (ZBH) Beats Q1 Earnings and Revenue Estimates

Medtech firm Zimmer Biomet Holdings beat Wall Street estimates for first-quarter profit on Thursday, on the back of robust demand for its devices that are used in knee and hip reconstruction procedures.

Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices

First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency1 basis First quarter diluted earnings per share were $0.84; adjusted1 diluted earnings per share were $1.94 Company reiterates full-year 2024 financial guidance WARSAW, Ind. , May 2, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2024.

Zimmer Biomet Announces First Quarter 2024 Financial Results

Bruker

Hologic

Illumina

Teleflex

Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.

Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?

Besides Wall Street's top -and-bottom-line estimates for Zimmer (ZBH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Unlocking Q1 Potential of Zimmer (ZBH): Exploring Wall Street Estimates for Key Metrics

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Zimmer (ZBH) is Poised to Beat Earnings Estimates Again

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Zimmer Biomet (ZBH) Q1 Earnings Expected to Decline

Stryker

SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.

SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?

Within the Hips business, Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery, banking on strategic product launches in the first quarter.

What's in the Cards for Zimmer Biomet (ZBH) in Q1 Earnings?

-- Zimmer Biomet Brings Joint Health  Education and the Importance of Movement to America's Fastest-Growing Sport, Engaging the 48.3 Million Players, Fans of the Sport, and Raising Awareness as a Trusted Partner for Joint Replacement-- WARSAW, Ind., April 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced partnerships with three top pickleball organizations in the United States, becoming the first and only medical device partner for the sport of pickleball.

Zimmer Biomet Becomes First and Only Official Medical Device Partner of Association of Pickleball Players, Professional Pickleball Association, and USA Pickleball

WARSAW, Ind. , April 3, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Thursday, May 2, 2024 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2024 Financial Results

Lantheus Holdings

Insulet

ResMed

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

5 Medical Product Stocks to Buy Amid Industry Challenges

Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

Becton, Dickinson and Co.

Globus Medical

Intuitive Surgical

Medtronic

Smith & Nephew

There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.

News for Zimmer Biomet Hlds Stock (ZBH)